QYOU USA and Chtrbox Influencer Marketing Teams Receive Multiple 2024 Accolades and Awards
Campaigns and Individuals Are Recognized Across a Variety of Categories and Competitions LOS ANGELES, MUMBAI, India and TORONTO, May 24, 2024 /PRNewswire/ – QYOU Media Inc., (TSXV: QYOU) (OTCQB: QYOUF) a company operating in India and the United States producing and distributing content c
Canadian Investment Regulatory Organization Trading Halt – DN
TORONTO, May 24, 2024 /CNW/ – The following issues have been halted by CIRO: Company: Delta 9 Cannabis Inc. TSX Symbol: DN All Issues: Yes Reason: Pending News Halt Time (ET): 8:00 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-liste
FalconX and SignalPlus: a Partnership Built for Crypto Options Traders
SINGAPORE, May 24, 2024 /PRNewswire/ — We are excited to announce a strategic partnership between FalconX, the world’s largest institutional digital asset prime broker and the first CFTC-registered swap dealer, and SignalPlus, an industry-leading crypto options OEMS (Order and Execution
Xiao-I Corporation Partners with Leading Bank to Revolutionize Knowledge Management with Advanced AI Technology
SHANGHAI, May 24, 2024 /PRNewswire/ — Xiao-I Corporation (NASDAQ: AIXI) (“Xiao-I” or the “Company”), a leading AI company announces an important partnership with a major Chinese banking institution to enhance its knowledge management. This partnership is expected to rev
NewSound Hearing Aid Celebrates 20th Anniversary
XIAMEN, China, May 24, 2024 /PRNewswire/ — On May 12, 2024, NewSound Hearing Aids commemorated two decades of groundbreaking work with a special anniversary event themed “New Sound Along the Way.” It included the grand opening of the new NewSound Innovation Showcase room, a seminar
61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreaking study reveals
STOCKHOLM, May 24, 2024 /PRNewswire/ — A pioneering study, presented today at the 61st ERA Congress, has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mortality in patients with type 2 diabetes and chronic ki
AbelZeta Announces Publication of Abstract for ASCO 2024 Annual Meeting
ROCKVILLE, Md., May 24, 2024 /PRNewswire/ — AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced tha
Alma Unveils Alma Harmony™ and Alma IQ™ in U.S. Market, Advancing Personalization in Aesthetic Treatments
The next generation of the world’s most versatile aesthetic workstation, alongside an intelligent skin analysis system, elevates the patient experience. CHICAGO, May 24, 2024 /PRNewswire/ — Alma, a global leader in energy-based medical and aesthetic solutions, announced the commercial de
HI-Bio Presents Positive Interim Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at 61st European Renal Association (ERA) Congress
Patients receiving nine-dose regimen over five months experienced deep and durable reduction in proteinuria, reaching up to ~50% mean reduction in UPCR at end of study at month 24 and over 18 months after last dose Patients across treatment arms exhibited stabilization in eGFR through 24 months, whi
